Global private equity and venture capital news and research

Imperial Innovations leads £15m funding round for allergy vaccine developer

11 Dec 2009

Imperial Innovations, a technology commercialisation and investment company that backs innovations from Imperial College London, has led a £15.25m (€16.8m) funding round in Circassia, an allergy T-cell vaccine developer.

Sorry, to get access to this you need to subscribe for free.

In order to view more content, sign-up to our free daily newsletter.

If you would like to read the premium stories, have complete access to our breaking news and Limited Partner magazine you need to become a Premium Subscriber.

Subscribe to AltAssets today

Login to AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016